Lilly has launched six early-stage clinical programs, and 34 discovery programs with a focus on incretins, amylins, and novel ...
On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial ...
San Francisco, USA-based Chai Discovery, the AI company building a computer-aided design suite for molecules, has announced a ...
Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...
The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...
Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with Eli Lilly and Company (Lilly) to accelerate biologics discovery using ...
People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.
The life sciences world is once again converging in San Francisco as the J.P. Morgan Healthcare Conference kicks off for 2026 ...
AI drug discovery startup Converge Bio raised $25 million in a Series A led by Bessemer Venture Partners, with additional ...
Swiss drugmaker Novartis has signed a licensing deal worth nearly $1.7 billion with privately held SciNeuro Pharmaceuticals ...
During Q4, ClearBridge International Growth EAFE Strategy underperformed its MSCI EAFE Index benchmark and MSCI EAFE Growth ...
As of Tuesday, January 13, AbCellera Biologics Inc.’s ABCL share price has dipped by 9.73%, which has investors questioning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback